Vintages and Valuations: Why Timing Is Everything in Biotech VC
In venture capital, your returns depend less on genius and more on calendar luck. Especially in biotech.
Venture capitalists like
The Last Cheques in Europe
Biotech, we were told, had entered its age of austerity. The days of bloated valuations and preclinical moonshots were over.
The Venture Winter: Rethinking Biotech's Funding Future Amidst Scarcity
The pronouncement that "It’s Never Been Harder to Make It in Venture Capital," as captured by Bloomberg,
Rethinking Biotech Financing
At the recent Capital for Cures gathering in Milan, a curated group of biotech innovators, investors, and family office leaders
The QALY: Health Economics’ Favorite Yardstick—or a Misguided Ruler?
If you’ve ever wondered how governments decide which new drugs to fund and which to reject, chances are the
How Europe Can Compete in the Global Biotech Race: Lessons from the Capital for Cures Event Series
If biotech were a footrace, Europe would be the competitor with flawless running shoes, world-class muscle tone—and one leg
The Mansion House Accord: Reinvigorating UK Investment or Merely Rebadging the Status Quo?
In July 2023, the United Kingdom government launched the Mansion House Compact, a voluntary commitment by nine of the country’
Whither ESG? The Curious Case of Pharma's Forgotten Acronym
Ah, ESG! Not long ago, you could hardly sip your oat milk latte—or endure a quarterly earnings call—without
Health Economics: Pharma’s Favorite Crystal Ball
Health economics is to pharma what a crystal ball is to a fortune teller—draped in mystique, full of promise,
ICER: The Gatekeeper of European Healthcare, or a Flawed Oracle?
The Incremental Cost-Effectiveness Ratio (ICER) is the darling of health economists and the bane of pharmaceutical companies. At its heart,
